FDA Approves First Subcutaneous Infliximab for Maintenance Therapy in UC and Crohn Disease

The approval of infliximab-dyyb as a maintenance therapy following IV infliximab for patients with moderately to severely active ulcerative colitis and Crohn disease was announced on October 22, 2023.

Related Keywords

Thomas Nusbickel ,Jean Frederic Colombel ,Icahn School Of Medicine At Mount Sinai ,Drug Administration ,Celltrion United States ,Icahn School ,Biologics License Application ,Celltrion United ,Infliximab ,Subcutaneous Infliximab ,Infliximab Dyyb ,